Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model

Nuclear Medicine and Biology

Volumn 37, Issue 2, 2010, Pages 157-165

  Hanin, François Xavier ^a   Pauwels, Stanislas ^a   Bol, Anne ^a   Breeman, Wout ^b   de Jong, Marion ^b   Jamar, François ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CA20948 tumor; DOTA Tyr3 octreotate; Gallium 68; Octreotide; PRRT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; GALLIUM 68; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DOTA TYR(1) OCTREOTATE; DOTA-TYR(1)-OCTREOTATE; DRUG DERIVATIVE; GALLIUM; OXYGEN; SINGLE HETEROCYCLIC RINGS; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; TRACER; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; IMAGE ANALYSIS; IN VIVO STUDY; ISOTOPE LABELING; MALE; NEUROENDOCRINE TUMOR; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RAT; RAT STRAIN; RELIABILITY; REPEAT PROCEDURE; TUMOR BLOOD FLOW; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; HALF LIFE TIME; HUMAN; METABOLISM; NEOPLASM; REPRODUCIBILITY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

ANIMALS; BIOLOGICAL TRANSPORT; DISEASE MODELS, ANIMAL; GALLIUM RADIOISOTOPES; HALF-LIFE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; NEOPLASMS; OCTREOTIDE; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RATS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SOMATOSTATIN; WATER;

EID: 76949088129     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.09.006     Document Type: Article

References (37)

1. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 3 (2000) 273-282
2. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 8 (1993) 716-731
3. Lamberts S.W., Bakker W.H., Reubi J.C., and Krenning E.P. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323 18 (1990) 1246-1249
4. Breeman W.A., de Jong M., de Blois E., Bernard B.F., Konijnenberg M., and Krenning E.P. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 32 4 (2005) 478-485
5. Hofmann M., Maecke H., Borner R., Weckesser E., Schoffski P., Oei L., et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28 12 (2001) 1751-1757
6. Jamar F., Barone R., Mathieu I., Walrand S., Labar D., Carlier P., et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30 4 (2003) 510-518
7. Maecke H.R., Hofmann M., and Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 46 Suppl 1 (2005) 172S-178S
8. Heppeler A., Froidevaux S., Eberle A.N., and Maecke H.R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7 9 (2000) 971-994
9. Krenning E.P., de Jong M., Kooij P.P., Breeman W.A., Bakker W.H., de Herder W.W., et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10 Suppl 2 (1999) S23-S29
10. Kwekkeboom D., Krenning E.P., and de Jong M. Peptide receptor imaging and therapy. J Nucl Med 41 10 (2000) 1704-1713
11. Valkema R., De Jong M., Bakker W.H., Breeman W.A., Kooij P.P., Lugtenburg P.J., et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32 2 (2002) 110-122
12. Kwekkeboom D.J., Bakker W.H., Kooij P.P., Konijnenberg M.W., Srinivasan A., Erion J.L., et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 28 9 (2001) 1319-1325
13. Otte A., Herrmann R., Heppeler A., Behe M., Jermann E., Powell P., et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26 11 (1999) 1439-1447
14. Valkema R., Pauwels S.A., Kvols L.K., Kwekkeboom D.J., Jamar F., de Jong M., et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46 Suppl 1 (2005) 83S-91S
15. Barone R., Pauwels S., De Camps J., Krenning E.P., Kvols L.K., Smith M.C., et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 19 9 (2004) 2275-2281
16. Vegt E., Wetzels J.F., Russel F.G., Masereeuw R., Boerman O.C., van Eerd J.E., et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47 3 (2006) 432-436
17. Barone R., Walrand S., Konijnenberg M., Valkema R., Kvols L.K., Krenning E.P., et al. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun 29 3 (2008) 283-290
18. Hukovic N., Panetta R., Kumar U., and Patel Y.C. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 137 9 (1996) 4046-4049
19. Froidevaux S., Hintermann E., Torok M., Macke H.R., Beglinger C., and Eberle A.N. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 59 15 (1999) 3652-3657
20. Huisman M.C., Reder S., Weber A.W., Ziegler S.I., and Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging 34 4 (2007) 532-540
21. Bol A., Melin J.A., Vanoverschelde J.L., Baudhuin T., Vogelaers D., De Pauw M., et al. Direct comparison of [13N]ammonia and [15O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation 87 2 (1993) 512-525
22. Breeman W.A., Kwekkeboom D.J., Kooij P.P., Bakker W.H., Hofland L.J., Visser T.J., et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 36 4 (1995) 623-627
23. Jonard P, Jamar F, Walrand S, Labar D, Mathieu I, Smith C, et al. Effect of peptide amount on biodistribution of 86Y-DOTA-Tyr3-octreotide (SMT487). J Nucl Med, Proceedings of the 47th SNM annual meeting 2000;260P.
24. Lemaire M., Azria M., Dannecker R., Marbach P., Schweitzer A., and Maurer G. Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. Drug Metab Dispos 17 6 (1989) 699-703
25. Marbach P., Briner U., Lemaire M., Schweitzer A., and Terasaki T. From somatostatin to Sandostatin: pharmacodynamics and pharmacokinetics. Digestion 54 Suppl 1 (1993) 9-13
26. FDA approved package insert of OctreoScan®. downloaded from. http://www.octreoscan.com/OctreoscanPI.pdf on september, 14, 2009
27. Dorr U., Rath U., Sautter-Bihl M.L., Guzman G., Bach D., Adrian H.J., et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 20 5 (1993) 431-433
28. Janson E.T., Kalkner K.M., Eriksson B., Westlin J.E., and Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol 26 8 (1999) 877-882
29. Forrer F., Uusijarvi H., Storch D., Maecke H.R., and Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 46 8 (2005) 1310-1316
30. Goglia U., Ferone D., Sidoti M., Spaziante R., Dadati P., Ravetti J.L., et al. Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. Pituitary 11 1 (2008) 93-102
31. Astruc B., Marbach P., Bouterfa H., Denot C., Safari M., Vitaliti A., et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 45 7 (2005) 836-844
32. Highlights of Prescribing information for Sandostatin® LAR® Depot. available at. http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdf downloaded on September, 14, 2009
33. Bao A., Goins B., Dodd G.Dr., Soundararajan A., Santoyo C., Otto R.A., et al. Real-time iterative monitoring of radiofrequency ablation tumor therapy with 15O-water PET imaging. J Nucl Med 49 10 (2008) 1723-1729
34. Kunz P., Hoffend J., Altmann A., Dimitrakopoulou-Strauss A., Koczan D., Eisenhut M., et al. Angiopoietin-2 overexpression in morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. J Nucl Med 47 9 (2006) 1515-1524
35. Schmidt K., Hoffend J., Altmann A., Kiessling F., Strauss L., Koczan D., et al. Troponin I overexpression inhibits tumor growth, perfusion, and vascularization of morris hepatoma. J Nucl Med 47 9 (2006) 1506-1514
36. Schmidt K., Hoffend J., Altmann A., Strauss L.G., Dimitrakopoulou-Strauss A., Engelhardt B., et al. Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization. J Nucl Med 47 3 (2006) 543-551
37. Croteau E., Benard F., Bentourkia M., Rousseau J., Paquette M., and Lecomte R. Quantitative myocardial perfusion and coronary reserve in rats with 13N-ammonia and small animal PET: impact of anesthesia and pharmacologic stress agents. J Nucl Med 45 11 (2004) 1924-1930